Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
MWN-AI** Summary
Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for DTX401, a novel AAV gene therapy aimed at treating Glycogen Storage Disease Type Ia (GSDIa). The therapy—termed pariglasgene brecaparvovec—has been granted Priority Review status, with a Prescription Drug User Fee Act (PDUFA) action date set for August 23, 2026. If approved, DTX401 will be the first treatment to address the root cause of GSDIa, a rare and serious genetic disorder caused by a deficiency of the enzyme glucose-6-phosphatase (G6Pase).
According to Dr. Eric Crombez, Chief Medical Officer at Ultragenyx, current management strategies, primarily dietary modifications, place a significant burden on patients and their families, resulting in life-threatening hypoglycemic episodes and chronic complications. DTX401 aims to alleviate these issues by delivering stable G6Pase activity in liver cells, which normalizes glucose management.
The BLA submission is backed by data from a comprehensive clinical program involving 52 patients with follow-up of up to six years. Results from the Phase 3 GlucoGene study showed that patients receiving DTX401 had significant reductions in daily cornstarch intake while maintaining euglycemia and improved tolerability, leading to enhanced quality of life.
Manufactured entirely in the U.S. at Ultragenyx’s facility in Bedford, Massachusetts, DTX401 has received multiple designations from the FDA, including Rare Pediatric Disease and Fast Track designations. With approximately 6,000 individuals affected by GSDIa in commercially accessible regions, the potential approval of DTX401 represents a significant advancement for patients suffering from this challenging condition.
MWN-AI** Analysis
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has recently announced a significant step forward in the regulatory approval process for its AAV gene therapy, DTX401, for Glycogen Storage Disease Type Ia (GSDIa). The U.S. FDA has accepted its Biologics License Application (BLA) and granted a Priority Review status, with a Prescription Drug User Fee Act (PDUFA) action date set for August 23, 2026. This marks a potentially pivotal moment for Ultragenyx and its investor base.
Should DTX401 receive approval, it will be the first treatment designed to address the underlying causes of GSDIa, a serious condition affecting approximately 6,000 individuals in commercially accessible regions. The therapy’s demonstration of significant reductions in daily cornstarch requirements and improved patient quality of life positions it favorably in a market that currently lacks effective pharmacological options.
As a financial analyst, I advise investors to consider several factors regarding Ultragenyx’s prospects. First, the FDA's decision to expedite the BLA implies high confidence in the clinical data derived from the extensive Phase 3 GlucoGene study. This factor may bolster Ultragenyx's stock performance in the near term as market sentiment typically rallies around potentially groundbreaking therapies.
However, it is crucial to remain aware of the inherent risks involved in drug development, particularly with the clinical timelines and regulatory processes that can alter market expectations rapidly. Investors should closely monitor updates from Ultragenyx regarding regulatory feedback and upcoming milestones, including any potential manufacturing challenges at their new facility in Massachusetts.
In summary, while the acceptance of the BLA is a promising development for Ultragenyx and its stakeholders, a balanced approach that weighs both the considerable potential benefits and the risks associated with drug approval timelines is essential for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PDUFA action date set for August 23, 2026
If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa
NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Application (BLA) seeking approval of DTX401 AAV gene therapy (pariglasgene brecaparvovec) for the treatment of Glycogen Storage Disease Type Ia (GSDIa). The FDA granted the BLA Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 23, 2026.
“Current dietary approaches to managing GSDIa place an extraordinary burden on individuals and families while still leaving patients with significant medical needs, including the risk of potentially life-threatening episodes of acute hypoglycemia and accumulation of long-term complications over their lifetime,” said Eric Crombez, M.D., chief medical officer at Ultragenyx. “If approved, DTX401 would be the first treatment to address the disease at its root cause. We appreciate the FDA’s timely acceptance of the BLA and will continue to work with the Agency throughout its review process.”
The BLA is based on data from a rigorous clinical development program that includes 52 treated patients and up to six years of follow-up. Previously announced data from the randomized, double-blind, placebo-controlled Phase 3 GlucoGene study demonstrate that patients treated with DTX401 experienced significant and clinically meaningful reductions in both the quantity and frequency of daily cornstarch intake while maintaining low levels of hypoglycemia, improved levels of euglycemia, and improved fasting tolerance. These clinical benefits translated to meaningful improvements in patient-reported quality of life, as measured by the Patient Global Impression of Change (PGIC) scale. DTX401 was well tolerated, with an acceptable safety profile.
If approved, DTX401 will be manufactured entirely within the U.S. at the new Ultragenyx gene therapy manufacturing facility in Bedford, Massachusetts.
About DTX401 (pariglasgene brecaparvovec)
DTX401 is an investigational AAV8 gene therapy designed to deliver stable expression and activity of G6Pase under control of the native promoter to allow the treated liver cells to respond to normal hormonal signals intended to manage glucose, including insulin and cortisol. DTX401 is administered as a single intravenous infusion and has been shown in preclinical studies to improve G6Pase activity and reduce hepatic glycogen levels, a well-described biomarker of disease progression. DTX401 has been granted Rare Pediatric Disease designation, orphan drug designation, Fast Track designation, and regenerative medicine advanced therapy (RMAT) designation from the U.S. FDA, as well as orphan drug and PRIority MEdicines (PRIME) designations from the European Medicines Agency.
About Glycogen Storage Disease Type Ia (GSDIa)
GSDIa is a rare, serious, and life-threatening disease due to an inborn error of carbohydrate metabolism caused by pathogenic variants of the G6PC gene, which encodes G6Pase, an enzyme that is critical for the release of glucose from glycogen and other metabolic sources. Deficiency of G6Pase activity results in severe hypoglycemia during periods of fasting between meals and during the night, along with excess hepatic glycogen storage, metabolic derangements, and other disease related complications. Cornstarch is critical in the management of GSDIa throughout the day and night in providing an exogenous source of glucose to avoid sudden and severe drops in plasma glucose levels; however current management strategies carry a significant burden to patients and families. There are no approved pharmacologic therapies. GSDIa is estimated to affect approximately 6,000 people in commercially accessible geographies.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Forward-Looking Statements and Use of Digital Media
Except for the historical information contained herein, the matters set forth in this press release, including statements related to Ultragenyx's expectations and projections regarding its future operating results and financial performance, business plans and objectives for DTX401, expectations regarding the tolerability and safety of DTX401, expectations regarding the adequacy of clinical data to support the marketing application and approval of DTX401, the potential timing and success of, the marketing application and other regulatory approvals for DTX401, expectations regarding timing of receiving potential approval of DTX401, expectations regarding the prevalence of patients of DTX401, future regulatory interactions, expectations regarding the company’s ability to resolve with the FDA the observations in the complete response letter, and the value to be generated by DTX401, and future clinical and regulatory developments for DTX401 are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, collaboration with third parties, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainty of clinical drug development and unpredictability and lengthy process for obtaining regulatory approvals, the ability of the company to successfully develop DTX401, the company’s ability to achieve its projected development goals in its expected timeframes, risks related to adverse side effects, risks related to reliance on third party partners to conduct certain activities on the company’s behalf, the company’s limited experience in operating its own manufacturing facility, the ability of the company and its third party manufacturers to comply with regulatory requirements, our ability to successfully manage the expansion of our company, delays or unexpected costs and other adverse effects related to the recently announced strategic restructuring plan, smaller than anticipated market opportunities for the company’s products and product candidates, manufacturing risks, competition from other therapies or products, and other matters that could affect sufficiency of existing cash, cash equivalents and short-term investments to fund operations, the company’s future operating results and financial performance, the timing of clinical trial activities and reporting results from same, and the availability or commercial potential of Ultragenyx’s products and drug candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements.
For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 18, 2026, and its subsequent periodic reports filed with the SEC.
In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx’s Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).
Ultragenyx Contacts
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
FAQ**
What are the potential market implications for Ultragenyx Pharmaceutical Inc. (RARE) if DTX401 is approved by the FDA on the PDUFA action date of August 23, 2026?
How does the acceptance of the BLA for DTX401 reflect Ultragenyx Pharmaceutical Inc. (RARE)'s ability to navigate regulatory hurdles in developing treatments for rare diseases?
What financial impacts could the approval of DTX401 have on Ultragenyx Pharmaceutical Inc. (RARE), considering it addresses a critical need in the management of GSDIa?
In what ways has Ultragenyx Pharmaceutical Inc. (RARE) prepared for potential manufacturing challenges associated with DTX401’s approval and distribution?
**MWN-AI FAQ is based on asking OpenAI questions about Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).
NASDAQ: RARE
RARE Trading
9.97% G/L:
$22.73 Last:
996,923 Volume:
$21.40 Open:
